Liver disease develops as a consequence of uncontrolled inflammation and fibrosis resulting in global mortality of over 2 million deaths per year. Within our diverse Birmingham region, the high prevalence of obesity (30%), rising alcohol-use disorders, and social inequities, contribute to sustained pressures on liver services. All liver diseases are driven by immune dysregulation and persistent hepatic inflammation, resulting in cirrhosis, liver failure and hepatocellular carcinoma (HCC). Thus, new therapies targeting inflammation have the potential to prevent or reverse progression to end-stage liver disease.
Professor Phil Newsome
Professor Shish Shetty